Journal
EUROPEAN JOURNAL OF CANCER
Volume 43, Issue 6, Pages 974-978Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2007.01.018
Keywords
imatimb; cardiotoxicity; GIST
Categories
Funding
- NCI NIH HHS [5U10 CA11488-32, 5U10 CA11488-33, 2U10 CA11488-29, 5U10 CA11488-31, 5U10 CA11488-30, 5U10 CA11488-34] Funding Source: Medline
Ask authors/readers for more resources
Recent publications have suggested that imatinib (Glivec) may be cardiotoxic. We have therefore assessed the largest study on the agent performed in patients with gastrointestinal stromal tumours, randomising a daily dose of 400 mg versus 800 mg. 946 Patients were entered, 942 patients received at least one dose of imatinib. The median time on treatment was 24 months. A total of 24,574 exposure months could be analysed. We could not identify an excess of cardiac events in the study population. In 2 patients (0.2%) a possible cardiotoxic effect of imatinib could not fully be excluded. The current analysis of a large randomised prospective study could not confirm previous suggestions of imatinib induced cardiac toxicity. (C) 2007 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available